← All trials
NCT05693766
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 11, 2023
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2037
- First posted
- Jan 23, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- AgendiaCollaborator
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversitySponsor investigator
- Susan G. Komen Breast Cancer FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.